Organizer

Oct. 12 (Thu.) ,2017 09:30-11:30

Annex Hall
F203/F204

Simultaneous Interpretation

【O-5】 Cancer immunotherapy targeting immune regulatory mechanisms

Cancer immunotherapy is now in a new era as illustrated by recent clinical results showing effectiveness of immune-checkpoint blockade and CAR-T therapy. Efforts made in these two decades to improve the efficacy of cancer immunotherapy have revealed various immunosuppressive elements present in cancer patients, including immunosuppressive T cells and cytokines present in tumor micro-environments. This session discusses how effective anti-tumor immune responses can be evoked by targeting various cellular and molecular elements present in tumor tissues.

Coordinator

Shimon Sakaguchi

Specially Appointed Professor, Immunology Frontier Research Center, Osaka University

Cancer immunotherapy targeting regulatory T cells

Shimon Sakaguchi

Specially Appointed Professor, Immunology Frontier Research Center, Osaka University

NF-κB in the cross-hairs: Rethinking an old riddle

Guido Franzoso

Professor and Chair of Signal Transduction and Inflammation / Head of the Centre for Cell Signalling and Inflammation (CCSI), Imperial College London

Partnering in the development of immuno-oncology agents and
combinations

Michael Axelson

Head of Oncology, Japan Medical & Development, Bristol-Myers Squibb

Close Window